These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

216 related articles for article (PubMed ID: 23165980)

  • 1. Patterns of survival in lymphoplasmacytic lymphoma/Waldenström macroglobulinemia: a population-based study of 1,555 patients diagnosed in Sweden from 1980 to 2005.
    Kristinsson SY; Eloranta S; Dickman PW; Andersson TM; Turesson I; Landgren O; Björkholm M
    Am J Hematol; 2013 Jan; 88(1):60-5. PubMed ID: 23165980
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Elevated risk of venous but not arterial thrombosis in Waldenström macroglobulinemia/lymphoplasmacytic lymphoma.
    Hultcrantz M; Pfeiffer RM; Björkholm M; Goldin LR; Turesson I; Schulman S; Landgren O; Kristinsson SY
    J Thromb Haemost; 2014 Nov; 12(11):1816-21. PubMed ID: 25196979
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Clinical characteristic and outcome of lymphoplasmacytic lymphoma of non-Waldenstrom macroglobulinemia type: A Swedish lymphoma registry study.
    Brandefors L; Sander B; Lundqvist K; Kimby E
    Br J Haematol; 2022 Mar; 196(6):1362-1368. PubMed ID: 34959252
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Cause-specific mortality in individuals with lymphoplasmacytic lymphoma/Waldenström macroglobulinaemia, 2000-2016.
    Dalal NH; Dores GM; Curtis RE; Linet MS; Morton LM
    Br J Haematol; 2020 Jun; 189(6):1107-1118. PubMed ID: 32090327
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Risk of lymphoproliferative disorders among first-degree relatives of lymphoplasmacytic lymphoma/Waldenstrom macroglobulinemia patients: a population-based study in Sweden.
    Kristinsson SY; Björkholm M; Goldin LR; McMaster ML; Turesson I; Landgren O
    Blood; 2008 Oct; 112(8):3052-6. PubMed ID: 18703425
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Diffuse large B-cell lymphoma occurring in patients with lymphoplasmacytic lymphoma/Waldenström macroglobulinemia. Clinicopathologic features of 12 cases.
    Lin P; Mansoor A; Bueso-Ramos C; Hao S; Lai R; Medeiros LJ
    Am J Clin Pathol; 2003 Aug; 120(2):246-53. PubMed ID: 12931555
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Primary therapy and relative survival in patients with lymphoplasmacytic lymphoma/Waldenström macroglobulinaemia: a population-based study in the Netherlands, 1989-2018.
    Amaador K; Kersten MJ; Visser O; Brink M; Posthuma EFM; Minnema MC; Vos JMI; Dinmohamed AG
    Br J Haematol; 2022 Feb; 196(3):660-669. PubMed ID: 34605017
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Immune-related and inflammatory conditions and risk of lymphoplasmacytic lymphoma or Waldenstrom macroglobulinemia.
    Kristinsson SY; Koshiol J; Björkholm M; Goldin LR; McMaster ML; Turesson I; Landgren O
    J Natl Cancer Inst; 2010 Apr; 102(8):557-67. PubMed ID: 20181958
    [TBL] [Abstract][Full Text] [Related]  

  • 9. MYD88 mutant lymphoplasmacytic lymphoma/Waldenström macroglobulinemia has distinct clinical and pathological features as compared to its mutation negative counterpart.
    Patkar N; Subramanian PG; Deshpande P; Ghodke K; Tembhare P; Mascarenhas R; Muranjan A; Chaudhary S; Bagal B; Gujral S; Sengar M; Menon H
    Leuk Lymphoma; 2015 Feb; 56(2):420-5. PubMed ID: 24828863
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Clinical features of 16 cases of lymphoplasmacytic lymphoma/Waldenström macroglobulinemia].
    Wang JJ; Jing HM; Shen HW; Xu JS; Li M; Gao ZF; Ke XY
    Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2010 Dec; 18(6):1494-8. PubMed ID: 21176358
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Survival in monoclonal gammopathy of undetermined significance and Waldenström macroglobulinemia.
    Kristinsson SY; Björkholm M; Landgren O
    Clin Lymphoma Myeloma Leuk; 2013 Apr; 13(2):187-90. PubMed ID: 23490991
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Results of a randomized trial of chlorambucil versus fludarabine for patients with untreated Waldenström macroglobulinemia, marginal zone lymphoma, or lymphoplasmacytic lymphoma.
    Leblond V; Johnson S; Chevret S; Copplestone A; Rule S; Tournilhac O; Seymour JF; Patmore RD; Wright D; Morel P; Dilhuydy MS; Willoughby S; Dartigeas C; Malphettes M; Royer B; Ewings M; Pratt G; Lejeune J; Nguyen-Khac F; Choquet S; Owen RG
    J Clin Oncol; 2013 Jan; 31(3):301-7. PubMed ID: 23233721
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Lymphoplasmacytic lymphoma-Waldenstrom's macroglobulinemia.
    Vitolo U; Ferreri AJ; Montoto S
    Crit Rev Oncol Hematol; 2008 Aug; 67(2):172-85. PubMed ID: 18499469
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Lymphoplasmacytic lymphoma/waldenstrom macroglobulinemia: an evolving concept.
    Lin P; Medeiros LJ
    Adv Anat Pathol; 2005 Sep; 12(5):246-55. PubMed ID: 16210920
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Prognostic factors and primary treatment for Waldenström macroglobulinemia - a Swedish Lymphoma Registry study.
    Brandefors L; Melin B; Lindh J; Lundqvist K; Kimby E
    Br J Haematol; 2018 Nov; 183(4):564-577. PubMed ID: 30198549
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Clinical and biological characteristics of non-IgM lymphoplasmacytic lymphoma].
    Yu Y; Xiong WJ; Chen JW; Jiao Y; Yan YT; Wang Q; Zou DH; Liu W; Liu HM; Lyu R; Qiu LG; Yi SH
    Zhonghua Xue Ye Xue Za Zhi; 2022 Jul; 43(7):568-574. PubMed ID: 36709134
    [No Abstract]   [Full Text] [Related]  

  • 17. Nuclear protein dysregulation in lymphoplasmacytic lymphoma/waldenstrom macroglobulinemia.
    Roberts MJ; Chadburn A; Ma S; Hyjek E; Peterson LC
    Am J Clin Pathol; 2013 Feb; 139(2):210-9. PubMed ID: 23355206
    [TBL] [Abstract][Full Text] [Related]  

  • 18.
    Luo Y; Cao X; Pan Q; Li J; Feng J; Li F
    J Nucl Med; 2019 Dec; 60(12):1724-1729. PubMed ID: 31101745
    [No Abstract]   [Full Text] [Related]  

  • 19. Lymphoplasmacytic lymphoma and Waldenström macroglobulinemia.
    Naderi N; Yang DT
    Arch Pathol Lab Med; 2013 Apr; 137(4):580-5. PubMed ID: 23544948
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The addition of rituximab to front-line therapy with CHOP (R-CHOP) results in a higher response rate and longer time to treatment failure in patients with lymphoplasmacytic lymphoma: results of a randomized trial of the German Low-Grade Lymphoma Study Group (GLSG).
    Buske C; Hoster E; Dreyling M; Eimermacher H; Wandt H; Metzner B; Fuchs R; Bittenbring J; Woermann B; Hohloch K; Hess G; Ludwig WD; Schimke J; Schmitz S; Kneba M; Reiser M; Graeven U; Klapper W; Unterhalt M; Hiddemann W;
    Leukemia; 2009 Jan; 23(1):153-61. PubMed ID: 18818699
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.